Health / Medical Topics

    BCR/ABL1 Fusion Gene

    Definition 1

    A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of the ABL1 gene. There are 3 potential products that are formed depending on which BCR exon has the breakpoint. All of the protein products have constitutively active tyrosine kinase activity. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia. (NCI Thesaurus)

    Definition 2

    A gene formed when pieces of chromosomes 9 and 22 break off and trade places. The ABL gene from chromosome 9 joins to the BCR gene on chromosome 22, to form the BCR-ABL fusion gene. The changed chromosome 22 with the fusion gene on it is called the Philadelphia chromosome. The BCR-ABL fusion gene is found in most patients with chronic myelogenous leukemia (CML), and in some patients with acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). (NCI Dictionary)




    YOU MAY ALSO LIKE

    Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic…
    A molecular genetic abnormality in the kinase domain of the BCR-ABL fusion gene that results in resistance to tyrosine kinase inhibitors. …
    A multivalent antineoplastic vaccine comprised of the bcr-abl oncogene breakpoint fusion peptide that elicits a bcr-abl specific T-cell immune response. …
    A multipeptide vaccine consisting of five peptides derived from the bcr-abl p210-b3a2 breakpoint fusion protein with potential antineoplastic activity. Vaccination with bcr-abl…
    A protein made from pieces of two genes that get joined together. It is found in most patients with chronic myelogenous leukemia…
    A gene formed when pieces of chromosomes 9 and 22 break off and trade places. The ABL gene from chromosome 9 joins…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact